Cleveland’s ViewRay Inc., maker of the MRIdian Linac clinical MRI-guided radiation therapy system, added another $59.1 million in capital through a direct sale of common stock and warrants to an affiliate of Fosun International Ltd. This is publicly held ViewRay’s 17th round of funding since 2007, and the 11th under the watch of President and CEO Chris A. Raanes. The company has raised more than $400 million. "We are excited to complete this financing, which will enable us to scale up production and to continue investing in sales and marketing to meet the growing demand for the MRIdian Linac," Raanes said in a statement. "This significant investment provides further validation of our belief that MRIdian Linac will lead to a new standard of care in radiation oncology." With FDA approval to market its MRIdian Linac technology to hospitals and doctors, approval from the Japanese Ministry of Health, Labor and Welfare to market its MRIdian system there, and an uptick of orders for the equipment last year, some followers of ViewRay's stock are predicting that 2018 will be the year ViewRay reaches profitability.
